Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas
Efficacity of Paclitaxel in association or not with Bevacizumab in treatment of angiosarcoma
Angiosarcoma
DRUG: Paclitaxel|DRUG: Bevacizumab
Progression free rate after 6 months of treatment, Stable disease, complete response and partial response according to RECIST 1.1, after 6 months of treatment
Objective response at 3, 6, 9 months of treatment, Stable disease, complete response and partial response according to RECIST 1.1, at 3, 6, 9 months of treatment|Median progression-free rate, Median time for both cohort between :

* date of inclusion
* date of clinical or radiological progression, an average time period of 1 year|Global median survival, Median time for both cohort between :

* date of inclusion
* date of death whatever the cause, an average time period of 18 months|Tolerance, According to NCI-CTCAE v4.0, during the study|Correlation between efficacity and serum expression of anti angiogenic factors, Blood samples at different times, Day 1, 8, 15, 29 and 57|Correlation between efficacity and beta-tubuline III expression in tissue, Paraffin blocks, At baseline
Randomization is stratified :

* angiosarcoma in irradiated region : yes / no
* visceral angiosarcoma : yes / no

All patient will received a maximum of 6 cycles of weekly Paclitaxel (Arm A and B) in association or not with Bevacizumab (ArmB).

1 cycle = 28 days Treatment by Bevacizumab is to continue beyond the 6th cycle, until disease progression or unacceptable toxicity

Arm A and B:

Day 1, D8 and D15 Paclitaxel : 90 mg/mÂ², IV weekly with premedication

Arm B :

Day 1 and D15 Bevacizumab : 10 mg/kg and then, Bevacizumab : 15 mg/kg/3 weeks until disease progression or unacceptable toxicity